ABSTRACT
Women of sub-Saharan African ancestry have disproportionately higher incidence of aggressive, early-onset Triple Negative Breast Cancer (TNBC), and TNBC mortality across all race groups. Population-based comparative studies show racial differences in TNBC tumor biology, with higher prevalence of basal-like and Quadruple-Negative subtypes in African Americans (AA). However, most investigations relied on self-reported race (SRR) of primarily United States (US) populations. However, given that genetic admixture in AAs is extremely heterogenous, and race-correlated social determinants can translate into biological differences, the true association of African ancestry with TNBC biology and gene expression is currently unclear. To address this, we conducted RNAseq on an international cohort of AAs, west and east Africans with TNBC. Using genetic ancestry estimation in this African-enriched cohort, we identified 613 genes associated with African ancestry and more than 2200 genes associated with regional-level African ancestry. Functional enrichment and deconvolution revealed tumor-associated immune cell infiltration and activity.
STATEMENT OF SIGNIFICANCE Using a rigorous ancestry quantification process, we show that TNBC has ancestry-associated gene expression profiles, linked to immunological landscapes, which may contribute to racial differences in clinical outcomes. This is the first study to show the definitive link to tumor immunological landscape, associated with African ancestry, using a multiethnic African-enriched cohort.
Competing Interest Statement
CY received consultant/honorarium from Amgen, QED Therapeutics, and Riptide Biosciences. CY is an owner of stocks in Riptide Biosciences.
Funding Statement
This work was supported by funding from Susan G. Komen (awarded to LN), and from U54-MD007585-26 (NIH/NIMHD), U54 CA118623 (NIH/NCI), and Department of Defense Grant (PC170315P1, W81XWH-18-1-0589) awarded to CY. These studies were partly supported by 5U54CA118948 (NIH/NCI) and by institutional funds (Department of Pathology and School of Medicine of the University of Alabama at Birmingham, UAB) awarded to UM. We acknowledge the help provided by the UAB Tissue Biorepository Shared Facility grant of the UAB OCCC, P30CA013148.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Weill Cornell Medical College gave ethical approval for this work. IRB of Henry Ford Health System gave ethical approval for this work. IRB of University of Michigan gave ethical approval for this work. IRB of University of Alabama Birmingham gave ethical approval for this work. IRB of Komfo Anokye Teaching Hospital gave ethical approval for this work. IRB of Millennium Medical College St. Paul's Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Support: This work was supported by funding from Susan G. Komen (awarded to LN), and from U54-MD007585-26 (NIH/NIMHD), U54 CA118623 (NIH/NCI), and Department of Defense Grant (PC170315P1, W81XWH-18-1-0589) awarded to CY. These studies were partly supported by 5U54CA118948 (NIH/NCI) and by institutional funds (Department of Pathology and School of Medicine of the University of Alabama at Birmingham, UAB) awarded to UM. We acknowledge the help provided by the UAB Tissue Biorepository Shared Facility grant of the UAB OCCC, P30CA013148.
Conflicts of Interest: CY received consultant/honorarium from Amgen, QED Therapeutics, and Riptide Biosciences. CY is an owner of stocks in Riptide Biosciences.
Data Availability
The data generated in this study are not publicly available due to the nondisclosure of genetic data issued through the Ministries of Health at corresponding African sites. These data must be approved for use by these entities, but may be available upon reasonable request from the corresponding author.
